183236-36-4

Upstream product

• 58479-61-1 tert-butylchlorodiphenylsilane 
• 115-77-5 Pentaerythritol 

Downstream Products

• 880101-02-0 (5-(((tert-butyl(diphenyl)silyl)oxy)methyl)-2,2-dimethyl-1,3-dioxan-5-yl)methanol 
• 915079-72-0 2-[((tert-butyl)diphenylsiloxy)methyl]-2-{4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]benzyloxymethyl}propane-1,3-diol 
• 183236-37-5 (3-Allyloxy-2,2-bis-allyloxymethyl-propoxy)-tert-butyl-diphenyl-silane 
• 260268-26-6 2,2-dimethyl-1-nitrooxy-2,2-bis(nitrooxymethyl)-4-oxa-5,5-diphenyl-5-silaheptane 
• 183236-39-7 [3-(2-Azido-ethoxy)-2,2-bis-(2-azido-ethoxymethyl)-propoxy]-tert-butyl-diphenyl-silane 
• 752218-94-3 (3-Azido-2,2-bis-azidomethyl-propoxy)-tert-butyl-diphenyl-silane 
• 183236-38-6 2-[3-(tert-Butyl-diphenyl-silanyloxy)-2,2-bis-(2-hydroxy-ethoxymethyl)-propoxy]-ethanol 

Relevant academic research and scientific papers

CATIONIC LIPIDS

The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.

Nitrostated and nitrosylated prostaglandins, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

NUCLEOSIDE ANALOGUES OR SALTS THEREOF

It is an object to provide a nucleoside analog that can produce an oligonucleotide analog in which the two properties of chemical and biological stability, and the ability to form double strands, are excellent, and an oligonucleotide analog that includes

Novel drug delivery compositions

The present invention provides for a novel molecules useful for delivery of compounds to a mammal, more particularly for the intracellular delivery of nucleotides, nucleotide analogues or compounds with a heterocyclic base. Also provided for are novel therapeutic complexes comprising novel molecules complexed with nucleotide analogues or heterogeneous or homogenous oligomers comprised of nucleotide analogues.

Solid-supported synthesis of highly functionalized tripodal peptides with flexible but preorganized geometry: Towards potential serine protease mimics

Tripodal scaffold 1 has been used in the synthesis of a representative member of a library of serine protease mimics, possessing three independent functionalized peptide chains on a central core. Each peptide chain contains one residue of the classical ca

Synthesis and structure of 2-aryl-5,5-disubstituted-1,3-dioxanes and conversion into chiral (1,1,1-trishydroxymethyl) methane derivatives

Pentaerythritol, (1,1,1-trishydroxymethyl)methyl methane and (1,1,1-trishydroxymethyl)nitromethane are converted into 2-aryl-5,5-bis(hydroxymethyl), 2-aryl-5-hydroxymethyl-5-methyl- or 2-aryl-5-hydroxymethyl-5-nitro-1,3-dioxanes and a range of derivatives. X-Ray and NMR analysis establishes that the latter is obtained as a single diastereomer whose structure is unambiguously determined. These materials can be elaborated to chiral derivatives of the starting (1,1,1-trishydroxymethyl) methanes.

A pentaerythritol-based molecular scaffold for solid-phase combinatorial chemistry

(Matrix Presented) A convergent synthesis has been developed for the preparation of solid-phase bound construct 1, consisting of an orthogonally protected trifunctional core structure that is attached to TentaGel via a photocleavable linker.

Nucleosides and nucleotides. 182. Synthesis of branched oligodeoxynucleotides with pentaerythritol at the branch point and their thermal stabilization of triplex formation

To find an oligodeoxynucleotide (ODN) with triplex stabilization capability, we designed and synthesized novel branched ODNs 1 and 2 with pentaerythritols at their branch points. Branched ODNs 1 and 2 were synthesized on a solid support using bis(phosphoramidite) 11. The stability of the triplexes formed by branched ODNs 1 and 2 with (dA)21 or (dT)21, was studied by thermal denaturation. Branched ODN 1 formed a stable parallel T-AT-type triplex with (dA)21 (T(m) = 38.9 °C) in a buffer of 0.01 M sodium phosphate (pH 7.0) containing 0.5 M NaCl and 0.02 M MgCl2, while branched ODN 2 formed a stable antiparallel A · AT-type triplex with (dT)21 (T(m) = 44.2 °C) in the same buffer. The formation of these triplexes was also confirmed by circular dichroism (CD) measurements and a gel retardation assay.

Synthesis of chemically and functionally diverse scaffolds from pentaerythritol

Pentaerythritol (2,2-bis-hydroxymethyl-propane-1,3-diol) was converted into a series of mono-, di-, and trisubstituted derivatives, comprising allyl ethers and amino-alkyl ethers, by systematic chemical manipulation of the hydroxy groups. The remaining hydroxymethyl group in the case of the trisubstituted analog was functionalized with ether groups bearing terminal ω-carboxyl or ω-alkene groups. These derivatives are versatile templates and scaffolds for single, double, or triple substitution with appropriate ligands forming amides and esters, and allowing the attachment of the ω-alkene or ω-carboxyl group to solid support for combinatorial chemistry.